Corona Returns: First case of JN.1 subvariant of Covid-19 found in Kerala

[ad_1]

Presence of JN.1 subvariant of COVID-19 in India

The first case of presence of JN.1 subvariant of Covid-19 in India has come to light in Kerala. JN.1 is closely related to the BA.2.86 variant, also known as Pirola, which has been found in the US and China.

patients recovering at home

The patient from Thiruvananthapuram was tested positive for JN.1 on December 8 and has since recovered. Kerala is witnessing an increase in Covid cases, most of the cases are mild and patients are recovering at home. A mock drill is being conducted in health facilities to assess preparedness measures

Monitoring multiple points of entry

Kerala has seen a rising trend of Covid cases in the last few weeks, with government sources saying most of the Covid cases detected recently were mild and patients recovered at home without any treatment. An official said, The activity, which began on December 13, is being carried out under the supervision of district collectors and is likely to be completed by Monday,” he said. “The health ministry is in regular touch with the health department in Kerala and is monitoring various points of entry,” he said. Is “

Symptoms mild in people found Covid-19 positive

Dr Rajiv Jayadevan, co-chairman of the Indian Medical Association Covid Task Force, said the symptoms among those who have tested positive for Covid-19 are mild. “It is difficult to pinpoint the reason for this. However, we are seeing a rise in cases in Kerala and neighboring states, which is The reason could be that people are traveling from countries where cases are still high. The role of JN.1 is a sub-variant, BA.2.86, which is prevalent in many parts of the world, including India, Dr. Jayadevan said. has been found, also needs to be explored’

JN.1 first detected in US in September 2023

JN.1 was first detected in the US in September 2023. By the end of October, it contained less than 0.1% of the SARS-CoV-2 virus. According to the US Centers for Disease Control and Prevention (CDC), the continued growth of JN.1 suggests that it is either more infectious or better at evading the immune system. The CDC says, “At this time, there is no evidence that JN.1 presents an increased risk to public health compared to other currently circulating variants.”

[ad_2]

Source link